

Table of Contents	
Dedication	3
Acknowledgments	5
Abbreviations	17
List of Tables	21
List of Figures	23
Summary	25
1. Introduction	27
1.1 A historical overview of African trypanosomiasis	27
1.2 A current synopsis of human African trypanosomiasis <i>Trypanosoma brucei gambiense</i>	30
1.3 The Elimination Investment Case (EIC) for human African trypanosomiasis <i>Trypanosoma brucei gambiense</i>	34
1.3.1 Thesis objective	36
1.3.2 Thesis outline	36
2. Contemporary and emerging strategies for eliminating human African trypanosomiasis due to <i>Trypanosoma brucei gambiense</i> : review	38
2.1 Abstract	39
2.2 Introduction	40
2.3 Methods	42
2.4 Results: Tools for HAT control	43
2.4.1 Evolution of HAT control principles	43
2.4.2 Case detection, diagnostics and treatment	45
2.4.3 Vector control	46
2.4.4 Tools currently under development	47
2.5 Results: Scenarios for HAT control	51

2.5.1	Target areas and target population for Gambiense HAT control and elimination	53
2.6	Discussion	55
2.7	Acknowledgements	58
2.8	Funding	59
3.	A Literature Review of Economic Evaluations for a Neglected Tropical Disease: Human African Trypanosomiasis ("Sleeping Sickness")	60
3.1	Abstract	61
3.2	Background	62
3.3	Methods	64
3.3.1	Literature Search Strategy	64
3.3.2	Literature Screening & Inclusion/Exclusion Criteria	64
3.3.3	Quality Assessment and Critical Appraisal	65
3.4	Results	66
3.4.1	Literature Search Results	66
3.4.2	Quality Assessment and Critical Appraisal	67
3.4.3	Characteristics of Included Economic Evaluations	71
3.4.4	Interventions	74
3.4.5	Economic Evaluation Description	74
3.5	Discussion	91
3.5.1	Potential Use of Cost-Effective Modelling for HAT Control and Elimination	92
3.5.2	Potential Use of Economic Evaluation Methodology in HAT Control and Elimination	93
3.6	Conclusions	95
4.	Human African trypanosomiasis prevention, treatment and control costs: A systematic review	96

4.1	Abstract	97
4.2	Introduction	97
4.2.1	Prevention, treatment, control of HAT	98
4.3	Methods	100
4.4	Results	101
4.4.1	Prevention: vector control costs	101
4.4.2	Costs of treatment and hospitalization for HAT	108
4.4.3	Control costs for HAT	110
4.4.4	Economic burden	112
4.5	Discussion	114
4.6	Conclusion	115
4.7	Acknowledgments	116
5.	Seeing beyond 2020: An economic evaluation of contemporary and emerging strategies for elimination of <i>Trypanosoma brucei gambiense</i>	117
5.1	Summary	118
5.2	Introduction	119
5.3	Methods	120
5.3.1	Potential strategies for control and elimination	120
5.3.2	Health effect and economic modelling	123
5.3.3	Costing inputs, sources, perspective, and outcomes	125
5.3.4	Uncertainty analysis	126
5.3.5	Role of the funding source	127
5.4	Results	127
5.5	Discussion	133
5.6	Research in context	136

5.6.1	Evidence before this study	136
5.6.2	Added value of this analysis	136
5.6.3	Implications of all the available evidence	136
5.7	Contributors	137
5.8	Declaration of interest	137
5.9	Acknowledgements	137
6.	The elimination of “sleeping sickness” – who will pay the price?: Assessing the financial burden for the elimination of human African trypanosomiasis <i>Trypanosoma brucei gambiense</i> in sub-Saharan Africa	138
6.1	Abstract	139
6.2	Introduction	140
6.3	Methods	141
6.3.1	Defining control and potential elimination programs	142
6.3.2	Forecasting the financial impact of national programs	143
6.3.3	Forecasting financial protection (financial protection analysis (FPA))	144
6.4	Results	145
6.4.1	Financial impact	145
6.4.2	Financial risk protection	148
6.5	Discussion	151
6.5.1	Conclusion	153
6.6	Summary Box	154
6.7	Keywords	154
6.8	Funding	155
6.9	Authors contributions	155
6.10	Acknowledgements	155

7.	Its' time to lose control: Systems thinking and an analytic approach in the context of health systems integration for the elimination of 'sleeping sickness'	156
7.1	Abstract	157
7.2	Backgrounds	158
7.3	Overview of health systems in the context of Gambiense HAT	159
7.3.1	'Control' of Gambiense HAT in relation to the health system	159
7.3.2	Systems thinking for emerging technologies related to Gambiense HAT services	160
7.4	Potential analytical approach for systems integration	163
7.4.1	Control versus elimination scenarios	163
7.4.2	Modelling the health system	164
7.4.3	Potential impacts	166
7.5	Discussion	168
7.5.1	Are we ready to lose 'control'?	168
7.5.2	Being one step ahead of integration concerns	170
7.6	Concluding remarks' - Getting a grip'	172
8.	Ethical considerations for global health care decision making: Justice-enhance cost-effectiveness analysis of new technologies for <i>Trypanosoma brucei gambiense</i>	173
8.1	Summary	174
8.2	Introduction	175
8.2.1	Human African trypanosomiasis <i>T.b. gambiense</i>	176
8.3	Normative approach	177
8.3.1	Objects of Distribution: Multidimensional Metrics of Well-Being	178
8.3.2	Distributive Principles: Prioritization Norm	178
8.4	Structure of JE-CEA	180
8.4.1	Specification of Normative Proposition about Objects of Distribution	181

8.4.2	Specification of Prioritization Norm	182
8.5	Justice-enhance cost-effectiveness analysis for Gambiense HAT control and elimination strategies	186
8.5.1	Overview of Methods	186
8.5.2	Phase 0: Identify options of interest	186
8.5.3	Phase 1: Construct social justice assessments	189
8.5.4	Phase 2: Consider social justice impacts with CEA	193
8.6	Discussion	197
8.7	Limitations and directions for future work	199
8.8	Conclusion	201
8.9	Key words	201
8.10	Funding	202
8.11	Acknowledgments	202
8.12	Conflict of Interests Declaration	202
9.	Discussion	203
9.1	EIC results for investment decisions (direct applications)	206
9.1.1	EIC for the BMGF	206
9.1.2	Drug discovery funding case for Novartis Institute for Tropical Disease (NITD), Singapore	207
9.2	Lessons learned from the EIC	208
9.3	Further and continued research within the EIC	211
9.3.1	Governance and funding	211
9.3.2	Additional EIC questions unanswered	214
9.3.3	Methodology and use	215
9.3.4	EICs for other NTDs investment decisions	216
9.4	Conclusion	216

9.5	Recommendations towards HAT elimination	217
9.5.1	Immediate goals	217
9.5.2	Long-term goals	218
	References	219
	APPENDICES	259
	Appendix A: Chapter 1	260
	A.1 Guiding Questions (from Guide to Preparing EIC version 07.11.11)	260
	Appendix B: Chapter 3	262
	B.1 Search strategy	262
	B.2 Information, inclusion-exclusion criteria legend	263
	Appendix C: Chapter 5	264
	C.1 Methods (additional information)	264
	C.1.1 Description of potential 'strategies' for control or elimination	264
	C.1.2 Choice of health outcomes and measurement of effectiveness	265
	C.1.3 Disability adjusted life years (DALY)	265
	C.1.4 Coverage rate assumptions related to surveillance	266
	C.1.5 Discounting	268
	C.2 Input parameters	269
	C.2.1 Cost Functions and Parameterization	274
	C.3 Rationale for one-way sensitivity analysis	280
	C.4 Modelling	281
	C.4.1 Description	281
	C.4.2 Predictive accuracy	282
	C.5 Results (Strategies A thru E)	284
	C.5.1 Cost-effectiveness results, base case	284

C.5.2	One-way Sensitivity Analysis (OWSA)	285
C.5.2.1.	Sensitivity Analysis Results	285
C.5.3	Sensitivity analysis - Probability full elimination reached in low risk transmission areas with additional surveillance	287
C.5.4	Sensitivity analysis - Probability 'London Declaration'* targets reached in high and moderate transmission areas with varying coverage levels for active surveillance	288
C.5.5	Detailed Sensitivity analysis results	289
C.6	Elimination results (Full results refer to Appendix C.6)	295
C.6.1	Coverage results	295
C.7	Preliminary results for 12 strategies for control and elimination of Gambiense HAT	298
C.7.1	Description of all 12 strategies for control and elimination	298
C.7.2	Rationale for five main strategies in final manuscript	299
C.8	Probability of Elimination results (detailed)	301
C.8.1	Base case analysis results	301
C.8.2	One-way Sensitivity Analysis Results	302
Appendix D: Chapter 6		309
D.1	Priority setting exercise	309
D.2	Financial forecast	310
D.2.1	Health care expenditures	311
	National 'screen & treat' programs and vector control program costs	311
D.3	Financial protection analysis	312
D.3.1	Number of cases (household) estimations	312
D.3.2	Out-of-pocket (OOP) Household health expenditures related to T.b. gambiense	314
D.3.3	Summary of inputs for the Financial Protection Analysis (FPA)	316

Appendix E: Chapter 7	317
E.1 Summary of health systems actors and responsibilities	317
E.2 Inter-arrival time estimations	321
E.3 Bandundu Province, Health Zones, Djuma, Vanga, Bulungu	321